Pyxis Oncology, Inc.
PYXS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $16 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $16 | $0 | $0 | $0 |
| % Margin | 97.1% | – | – | – |
| R&D Expenses | $59 | $50 | $86 | $51 |
| G&A Expenses | $25 | $33 | $37 | $19 |
| SG&A Expenses | $25 | $33 | $37 | $19 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $21 | $0 | $0 | $0 |
| Operating Expenses | $105 | $82 | $123 | $70 |
| Operating Income | -$89 | -$82 | -$123 | -$70 |
| % Margin | -554.1% | – | – | – |
| Other Income/Exp. Net | $10 | $8 | $3 | -$6 |
| Pre-Tax Income | -$79 | -$74 | -$121 | -$76 |
| Tax Expense | -$2 | $0 | $0 | $0 |
| Net Income | -$77 | -$74 | -$121 | -$76 |
| % Margin | -478.9% | – | – | – |
| EPS | -1.32 | -1.85 | -3.57 | -2.53 |
| % Growth | 28.6% | 48.2% | -41.1% | – |
| EPS Diluted | -1.32 | -1.85 | -3.57 | -2.53 |
| Weighted Avg Shares Out | 58 | 40 | 33 | 32 |
| Weighted Avg Shares Out Dil | 58 | 40 | 33 | 32 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $7 | $3 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | $2 | $1 | $1 |
| EBITDA | -$66 | -$80 | -$123 | -$69 |
| % Margin | -405.8% | – | – | – |